Article

Alphaeon enters agreement with PhysIOL for trifocal lens technology

Alphaeon Corp. announced it has entered into a definitive agreement with PhysIOL SA, of Belgium, to jointly develop and commercialize an exclusive Alphaeon-branded trifocal lens technology.

Las Vegas-Alphaeon Corp. announced it has entered into a definitive agreement with PhysIOL SA, of Belgium, to jointly develop and commercialize an exclusive Alphaeon-branded trifocal lens technology.

Specific terms of the agreement were not disclosed in a statement from the company.

PhysIOL’s research and development has produced a range of innovative products, designed in partnership with ophthalmic surgeons, as well as specialized research centers and universities. This partnership enables Alphaeon to bring PhysIOL trifocal lens technology to the United States for the first time, according to the statement.

 

“Alphaeon’s development and regulatory capabilities combined with our expertise in design and manufacturing of trifocal IOL technologies make this an ideal partnership,” said Marc Nolet, chief executive officer (CEO) of PhysIOL. “Additionally, we’re excited to leverage Alphaeon’s market access through its highly innovative ShoutMD proprietary social commerce platform.”

“We are very pleased to collaborate with PhysIOL,” said Robert E. Grant, CEO of Alphaeon. “With this new agreement, we will seek to advance the premium category for patients looking for excellent visual acuity outcomes across their range of vision, at near, mid, and distance.”

Related Videos
2 experts are featured in this series.
Image credit: ©Ophthalmology Times
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Wendy Lee, MD, talks about functional oculoplastics and aesthetics at EnVision Summit 2025
1 expert is featured in this series.
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
© 2025 MJH Life Sciences

All rights reserved.